
- Volume 0 0
PRODUCT Hotline
Lamotrigine Tablets
Lamotrigine Tablets, manufactured by Teva Pharmaceuticals (North Wales, PA), are indicated as adjunctive therapy for partial seizures and the generalized seizures of Lennox–Gastaut syndrome in adults and pediatric patients (≥2 years of age). The tablets also are indicated for conversion to monotherapy in adults with partial seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. The product is AB-rated and bioequivalent to Lamictal Tablets (GlaxoSmithKline).
For More Information:
888-TEVA USA (888-838-2872)
1500PRO Ultra Premium Blood Pressure Monitor
The 1500PRO Ultra Premium Blood Pressure Monitor with no wrap cuff, manufactured by Omron Healthcare (Bannockburn, IL), is an automatic cuff model that fits regular and large arms. The blood pressure monitor detects morning hypertension and irregular heartbeat; features memory for 2 users and a total of 200 measurements, and provides morning and evening averaging. The product also comes with Intellisense technology that applies the correct amount of pressure for fast, accurate, and more comfortable readings.
For More Information:
SyrSpend SF
active powders and oral solid dosage forms into a liquid suspension. It saves time during compounding. In addition, the product is buffered to pH 4.2 for enhanced compatibility and has a very low osmolality, making it suitable for pediatric and geriatric patients. The sugar-free SyrSpend SF is available in unflavored, cherry, and grape formulations.
For More Information:
800-423-6967
Articles in this issue
about 17 years ago
Case Studiesabout 17 years ago
Can You Read These Rxs?about 17 years ago
Cholesterol Watchabout 17 years ago
Asthma Watchabout 17 years ago
Diabetes Watchabout 17 years ago
Pharmacy Technology Newsabout 17 years ago
Compounding Hotlineabout 17 years ago
Arthritis Watchabout 17 years ago
Women's Health Watchabout 17 years ago
Pharmacy Technology ProductsNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.